Compare ACADIA Pharmaceuticals Inc. (ACAD) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs DuPont de Nemours Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while DuPont de Nemours Inc trades at $136.53 (market cap $18.85B). The key difference: DuPont de Nemours Inc is far larger — about 4.2× ACADIA Pharmaceuticals Inc.'s market cap, and DuPont de Nemours Inc pays a 1.72% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DD | |
|---|---|---|
Market Cap | $4.49B | $18.85B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $154.59 |
52-Week Low | $20.06 | $87.72 |
Enterprise Value | $3.69B | $21.31B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DuPont (DD) trades at $139.61, down 0.21% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten estimates, including Q1 2026 EPS of $1.65 versus $1.44 expected, though revenue declined to $6.85B in 2025. The company executed a 3:1 reverse stock split in June 2026 and maintains dividend payments, highlighting financial restructuring efforts amid mixed segment performance.
The outlook is cautiously optimistic with a consensus price target of $227.20, implying significant upside, but risks include persistent net losses, weak Q3 guidance concerns, and macroeconomic pressures on industrial segments. Investment appeal hinges on margin improvement and successful portfolio repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
